Statistically Significant Phase II Clinical Results for Prophylactic Use of rhITF in Mucositis Published In Journal of Clinical Oncology

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.